肺真菌病治疗进展  

The Advances of Treatment for Pulmonary Mycosis

作　　者：董荔[1] 

机构地区：[1]复旦大学呼吸病研究所

出　　处：《医药导报》2001年第1期28-29,共2页Herald of Medicine

摘　　要：简述几种常见肺真菌病临床药物治疗方法的进展。两性霉素B仍是治疗免疫抑制宿主危重的、快速发展的肺真菌病的首选药物 ,脂类制剂可用于不能耐受两性霉素B毒副作用的患者。氟康唑对肺念珠菌病、肺隐球菌病、肺球孢子菌病中的治疗是有效的 ,伊曲康唑在肺曲菌病、肺组织胞浆菌病。In this paper, the advances of the treatment for the most common pulmonary mycosis is introduced, and the recommended medications described. It is indicated that amphotericin B is still the first choice for the treatment of severe and rapidly progressive pulmonary mycosis. Lipid formulations of AmB can be used for those refractory or intolerant to the conventional amphotericin B. Fluconazole has proved effective in treating pulmonary candidosis, cryptococosis and coccidioidomysis. Itraconazole has been widely used in the treatment of pulmonary aspergillosis, histoplasmosis ans coccidioidomycosis.

关 键 词：肺真菌病 抗真菌药物 肺念珠菌病 肺曲菌病 治疗 

分 类 号：R519.05[医药卫生—内科学] R563[医药卫生—临床医学]